It takes an average of 12 years for a new drug to go from the preliminary molecular compound research to the successful market. There are tens of thousands of new drugs under research around the world, with tens of billions of dollars in R&D investment every year, from target, clinical, capital to intellectual property, production and commercialization, any link will be critical to the ultimate direction of new drug research and development influences.

In the context of gradual increase in costs and continuous extension of the R&D cycle, the division of labor in the pharmaceutical industry chain has become increasingly significant. It has become an industry trend for pharmaceutical companies to entrust their own R&D and production operations to other specialized companies. CDMO (Contract Development and Manufacturing Organization) has gradually become an important link in the R&D industry chain of pharmaceutical companies.

The core value of CDMO is to help pharmaceutical companies focus on the commercialization stage after listing through their own technological advantages and capacity scale, to obtain greater development opportunities. According to Frost & Sullivan's forecast, the global CDMO market will increase from USD 73 billion in 2019 to USD 92 billion in 2021, with a compound growth rate of 12.3%.

As China’s NMPA joins the ICH, the review of innovative drugs has accelerated, the consistency evaluation of generic drugs has become normal, and the MAH system has been further promoted. Favorable policies have continued to be introduced. While the domestic CDMO industry is facing fierce competition, it has also ushered in unprecedented development opportunities.